With their 5-minute quiz, the company can determine if you are eligible for the medication and what is the best approach for your weight loss goals
Subsequently, a phase 3 trial in the same population (NCT04524351) concluded in December 2023 and a peer-reviewed publication of results is pending, but the company (Annovis) reported significantly better motor outcomesMDS-UPDRS part II, III, II + III total scoreversus placebo in patients diagnosed over 3 years before enrolment and in patients with a postural instability and gait difficulty phenotype, as well as a halting in cognitive decline as measured by the Mini-Mental State Examination (MMSE) both in the entire PD cohort and in participants with mild dementia (MMSE scores between 20 and 26 [108])
Chen, L., Sun, S., Gao, Y
If you're struggling, don't be afraid to reach out to your doctor to ask for advice
What Are GLP1 Receptor Agonists